Search Results for: covid-19
Articles
CordenPharma Colorado Expands Lipid Excipients Purfication April 21, 2021
In response to the COVID-19 pandemic, mRNA (messenger RNA) vaccines have catapulted to center stage of the pharmaceutical and biotechnology...AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for Grade 1 Immune Checkpoint Inhibitor-Associated Colitis April 14, 2021
AzurRx BioPharma, Inc. recently announced it has entered into an agreement with PPD, Inc. for its planned Phase 1b/2a clinical trial evaluating proprietary formulations of micronized….
Calixar Invests in Pipeline of Highly Druggable Membrane Protein Targets & Native Antigens April 14, 2021
Calixar recently announced its €1M ($1.2M) investment in a new pipeline of complex therapeutic targets and native antigens of high...Cidara Therapeutics Announces Agreement With Janssen to Develop & Commercialize AVCs for the Prevention & Treatment of Influenza April 8, 2021
Cidara Therapeutics, Inc. recently announced it has entered into an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals, Inc. to develop and commercialize….
SPECIAL FEATURE - Excipients: Far From Inactive March 29, 2021
Contributor Cindy Dubin speaks with several innovative excipient companies that assert novel excipients – agglomerated, co-processed, and multifunctional – actively and safely affect formulation stability, solubility, and bioavailability as well as foster faster drug disintegration.
GLOBAL REPORT – 2020 Global Drug Delivery & Formulation Report: Part 2, Notable Drug Delivery and Formulation Product Approvals of 2020 March 29, 2021
In part 2 of this 4-part series, PharmaCircle, in collaboration with Drug Development & Delivery, focuses on notable drug delivery and formulation product approvals.
IONTAS Identifies Novel SARS-CoV-2 Neutralizing Antibodies March 25, 2021
IONTAS Limited and FairJourney Biologics S.A recently announced the identification of neutralizing antibodies, which bind to multiple emerging SARS-CoV-2 variants....Timber Pharmaceuticals Announces 50% Enrollment in Phase 2b CONTROL Study March 17, 2021
Timber Pharmaceuticals, Inc. recently announced 50% of patients in the Phase 2b CONTROL study evaluating TMB-001 (topical isotretinoin) in patients...FSD Pharma Enters License Agreement to Develop FDA-Approved Veterinary Drugs March 17, 2021
FSD Pharma recently announced it has entered into a license agreement with Innovet Italia S.R.L., under which Innovet granted the...AC Immune Announces New Clinical Results in Down Syndrome, Plans for Future Development of Anti-Amyloid-Beta Vaccine March 17, 2021
AC Immune SA recently announced plans to advance its novel anti-amyloid-beta (Abeta) vaccine into mid-stage clinical testing to treat and...AIM ImmunoTech Announces First Healthy Subjects Dosed in Phase 1 Intranasal Ampligen Clinical Study March 10, 2021
AIM ImmunoTech Inc. recently announced it has dosed the first healthy subjects in its Phase 1 clinical study on the...Codex DNA Releases World’s First Synthetic Genomes for Emerging SARS-CoV-2 Variants March 10, 2021
Codex DNA, Inc., recently announced the release of the world’s first full-length synthetic genomes for two emerging variants of the...Veru Receives FDA Agreement to Advance VERU-111 Into Phase 3 Study March 4, 2021
Veru Inc. recently announced the FDA agreed in an End of Phase 2 meeting, to advance VERU-111 into a Phase 3 registration clinical study based on the clinically meaningful benefits observed with….
Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology March 4, 2021
Qualigen Therapeutics, Inc. recently announced it has entered into a Material Evaluation and Option Agreement with the University College London...SPECIAL FEATURE - Improving Bioavailability & Solubility: Each Molecule Is Unique March 1, 2021
Contributor Cindy H. Dubin speaks with several innovative companies to discuss novel approaches to improving bioavailability and solubility that have one commonality: they treat each molecule as an individual.
GLOBAL REPORT - 2020 Global Drug Delivery & Formulation Report: Part 1, a Global Review March 1, 2021
In part 1 of this 4-part series, PharmaCircle, in collaboration with Drug Development & Delivery, focuses on a global review of 2020 product approvals.
CELL & GENE THERAPY - End-to-End Cell & Gene Therapy – From Development to Commercialization – Buy or Build? March 1, 2021
Aldo Romano and Emily Moran, MBA, discuss how the life science industry must bring technology solutions to the table while at the same time securing the capacity to develop and manufacture groundbreaking cures so patients and society can tap the benefits of cell and gene therapies.
EXECUTIVE INTERVIEW - Pharmaceutics International, Inc: Getting Back to its Roots March 1, 2021
Sridhar Krishnan, Pii’s Senior Vice President, Operations and Strategic Initiatives, discusses how manufacturing is not solely where Pii wanted to be, so the company made a concerted effort to get back to its CDMO roots.
IMMUNE ACTIVATORS - Enhancing Cell Adhesion to Safely Improve Effectiveness of Vaccines & Cancer Immunotherapies March 1, 2021
Siddhartha De, PhD, and Peter Vanderslice, PhD, present their research on the use of proprietary, orally available compounds that can activate the immune system to enhance the effectiveness of vaccines as well as immuno-oncology therapies for cancer, especially in patient populations that are most vulnerable to disease.
Mateon Therapeutics & Windlas Biotech Launch India's First Combined Lung Therapy & AI Telemedicine Solution February 24, 2021
Mateon Therapeutics, Inc. and Windlas Biotech Pvt. Ltd. recently announced the launch in India of PulmoHeal, a first-of-its-kind integrated, consumer-centric...
